Clinical Trial Update: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in combination with lenvatinib for advanced hepatocellular carcinoma refractory to IO-based therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED